{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:12:15Z","timestamp":1785363135641,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T00:00:00Z","timestamp":1569369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.clgc.2019.09.013","type":"journal-article","created":{"date-parts":[[2019,9,26]],"date-time":"2019-09-26T17:39:33Z","timestamp":1569519573000},"page":"62-68.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes"],"prefix":"10.1016","volume":"18","author":[{"given":"Jakob N.","family":"Henriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernille","family":"B\u00f8ttger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina K.","family":"Hermansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren A.","family":"Ladefoged","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hamilton-Dutoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas L.","family":"Fink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frede","family":"Donskov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2019.09.013_bib1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ejca.2013.10.010","article-title":"Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2","volume":"50","author":"Soerensen","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.013_bib2","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.013_bib3","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.clinthera.2012.01.014","article-title":"Pazopanib for the treatment of metastatic renal cell carcinoma","volume":"34","author":"Pick","year":"2012","journal-title":"Clin Ther"},{"key":"10.1016\/j.clgc.2019.09.013_bib4","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3109\/0284186X.2013.782103","article-title":"Risk of liver toxicity with the angiogenesis inhibitor pazopanib in cancer patients","volume":"52","author":"Kapadia","year":"2013","journal-title":"Acta Oncol"},{"key":"10.1016\/j.clgc.2019.09.013_bib5","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/j.ejca.2015.03.019","article-title":"Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients","volume":"51","author":"Powles","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.013_bib6","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.1200\/JCO.2011.41.0332","article-title":"Severe pazopanib-induced hepatotoxicity: clinical and histologic course in two patients","volume":"30","author":"Klempner","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clgc.2019.09.013_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.2217\/pgs.13.24","article-title":"Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors","volume":"14","author":"Spraggs","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clgc.2019.09.013_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/sj.bjc.6605653","article-title":"Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism","volume":"102","author":"Xu","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.09.013_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.bcp.2017.01.002","article-title":"Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: implications for hyperbilirubinemia","volume":"129","author":"Miners","year":"2017","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.clgc.2019.09.013_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2019.09.013_bib11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2019.09.013_bib12","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib versus sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clgc.2019.09.013_bib13","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-18-0291","article-title":"Goldilocks dosing of TKIs: a dose that is just right leads to optimal outcomes","volume":"24","author":"Rini","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.09.013_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/tpj.2016.58","article-title":"Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses","volume":"17","author":"Campbell","year":"2017","journal-title":"Pharmacogenom J"},{"key":"10.1016\/j.clgc.2019.09.013_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2133\/dmpk.DMPK-14-RG-031","article-title":"Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia","volume":"29","author":"Abumiya","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1016\/j.clgc.2019.09.013_bib16","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2217\/pgs-2016-0063","article-title":"Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity","volume":"17","author":"Bins","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.clgc.2019.09.013_bib17","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/jcph.627","article-title":"UGT1A1 genotype-dependent dose adjustment of belinostat in patients with advanced cancers using population pharmacokinetic modeling and simulation","volume":"56","author":"Peer","year":"2016","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.clgc.2019.09.013_bib18","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1158\/1078-0432.CCR-15-2044","article-title":"HLA-B*57:01 confers susceptibility to pazopanib-associated liver injury in patients with cancer","volume":"22","author":"Xu","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.09.013_bib19","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/j.jhep.2010.09.028","article-title":"Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma","volume":"54","author":"Xu","year":"2011","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.clgc.2019.09.013_bib20","series-title":"Votrient. Summary of product characteristics. Novartis","year":"2018"},{"key":"10.1016\/j.clgc.2019.09.013_bib21","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-17-2652","article-title":"Pazopanib exposure relationship with clinical efficacy and safety in the adjuvant treatment of advanced renal cell carcinoma","volume":"24","author":"Sternberg","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2019.09.013_bib22","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1038\/bjc.2014.503","article-title":"Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma","volume":"111","author":"Suttle","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2019.09.013_bib23","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s10147-013-0558-1","article-title":"Usefulness of one-point plasma SN-38G\/SN-38 concentration ratios as a substitute for UGT1A1 genetic\u00a0information after irinotecan administration","volume":"19","author":"Hirose","year":"2014","journal-title":"Int J Clin Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302824?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767319302824?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:31:12Z","timestamp":1761564672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767319302824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1558767319302824"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.013","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pazopanib-Induced Liver Toxicity in Patients With Metastatic Renal Cell Carcinoma: Effect of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety, and Patient Outcomes","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2019.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}